Ketamine & Related Compounds International Journal Club

Ketamine & Related Compounds International Journal Club

A series of free, short, 30-minute webinars held every two weeks, held on the 2nd and 4th Tuesdays at 12:30pm EST (usually 9:30am Pacific, 5:30pm GMT, 11:00pm Indian Standard).

Upcoming Journal Club Presentations

The next webinar will be held on 23rd April 2024. Details to follow.

Past Journal Club Presentations

32. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial

32. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trialTuesday 26th July 2022 | 12.30pm EST | 5.30pm UKThomas D Hull, Matteo Malgaroli,...

read more
9. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept Trial

9. Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept Trial

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept TrialTuesday 23rd March 2021 12.30pm EST; 5.30pm UKDomany Y,...

read more
3. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence 

3. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence 

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of ExcellenceTuesday 8th December 2020 12.30pm EST; 5.30pm...

read more